Skip to content

Acupuncture therapy in reducing high blood pressure

A randomised controlled trial to assess the effectiveness of acupuncture in reducing high blood pressure among patients with essential hypertension in the Chitwan district of Nepal

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2017/029
Enrollment
Unknown
Registered
2017-09-06
Start date
2017-10-09
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

The trial will be conducted in selected health facilities in Chitwan, Nepal Once the participants meet the inclusion and exclusion criteria at the screening visit, there will be one week run in perio

Sponsors

Ministry of Health, Government of Nepal
Lead Sponsor
Barefoot clinic UK
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Men and women aged 30 - 70 years. 2. Participants who meet the diagnostic criteria of hypertension according to the International society of Hypertension Guidelines, 2013

Exclusion criteria

Exclusion criteria: Participants diagnosed with disorders in heart, kidney, thyroid gland, diabetes, neurological disease, skin or bleeding disorders and currently on any drugs or medications for any other chronic disease.

Design outcomes

Primary

MeasureTime frame
Change in systolic and diastolic blood pressure. Outcome will be measured using standardized stethoscopes and sphygmomanometers, by following standard measurement techniques. [3 times a week for 6 weeks done at each visit during the intervention phase and once a week at follow up phase for 6 weeks. Blood pressure will be measured just before the treatment, during the treatment and after the treatment.]

Secondary

MeasureTime frame
Any adverse events due to the intervention defined as, pain, swelling around the intervention area. The grading will be done as : Very Mild, Mild, Moderate, Severe to Very Severe [3 times a week for 6 weeks done at each visit during the intervention phase and once a week at follow up phase for 6 weeks.]

Countries

Nepal

Contacts

Public ContactProf. Dr. Anjani Kumar Jha

Executive Chairman

dranjanikj@gmail.com977-014227460

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026